Drugs / triacetyluridine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00004233 | Feb 2001 → Jan 2007 | esophageal cancer, gastric cancer | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00024427 | Feb 2001 → Feb 2006 | malignant pancreatic neoplasm, poisoning | Wellstat Therapeutics | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00044785 Background | Aug 2002 → Mar 2004 | cancer | Wellstat Therapeutics | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | triacetyluridine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00004233 ↗ |
| Route | Oral | “receive oral triacetyluridine every 8 hours” NCT00024427 ↗ |